Latest Headlines

  1. SN BioScience Received US FDA Orphan Drug Designation For Its Nano Anti-Cancer Drug 'SNB-101' On Gastric Cancer. 12/23/2025

    SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API: SN-38) which is a polymer nanoparticle drug under phase 1b/2 clinical trial for small cell lung cancer.

  2. GC Biopharma Secures IND Approval For Phase 1 Clinical Trial Of COVID-19 mRNA Vaccine In Korea 12/22/2025

    GC Biopharma (006280.KS), a leading global biopharmaceutical company, announced today that Ministry of Food and Drug Safety (MFDS) in South Korea has approved the Investigational New Drug (IND) application for the Phase 1 clinical trial of "GC4006A", mRNA (messenger RNA) vaccine candidate for COVID-19.

  3. New ALS Drug Stabilizes Decline With Improved Strength, Mobility For Some 12/22/2025

    Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline of neurological function that eventually robs them of the ability to move, speak, eat or breathe.

  4. Flagship Pioneering And Repertoire® Immune Medicines Announce Agreement To Identify T Cell-Targeted Immune Medicines For Prostate Cancer Under Strategic Partnership With Pfizer 12/22/2025

    Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded Repertoire® Immune Medicines will identify and optimize TCR bispecifics for metastatic prostate cancer.

  5. Breakthrough Set To Accelerate Osteoporosis Drug Development 12/22/2025

    Millions of osteoporosis patients worldwide are set to benefit from a major international breakthrough which will transform how new treatments for the debilitating disease are developed.

  6. Egetis Therapeutics Initiates New Drug Application In The USA For Emcitate (Tiratricol) For MCT8 Deficiency 12/19/2025

    Egetis Therapeutics AB (publ) (“Egetis” or the “Company”), today announced that the Company has initiated a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for Emcitate (tiratricol), its investigational drug for the treatment of MCT8 deficiency.

  7. Beren, Through Its Subsidiary Mandos, Submits New Drug Application To U.S. FDA For Adrabetadex In Infantile-Onset NPC 12/19/2025

    Beren Therapeutics P.B.C. (“Beren”) today announced that its subsidiary Mandos LLC (“Mandos”) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for adrabetadex, an investigational therapy for the treatment of infantile-onset Niemann-Pick disease type C (NPC).

  8. Accelerating Next-Generation Drug Discovery With Click-Based Construction Of PROTACs 12/18/2025

    In 2001, chemists K. Barry Sharpless, Hartmuth C. Kolb, and M. G. Finn introduced click chemistry, a concept in which organic molecules can be rapidly and reliably joined to form more complex structures. They recognized that many natural compounds are assembled through efficient carbon-heteroatom (C-X) bond formation, particularly with nitrogen, oxygen, and sulfur, and they sought to replicate this in the laboratory.

  9. Meiji Seika Pharma Partners With MBC Biolabs To Strengthen Global Innovation In Drug Discovery 12/18/2025

    Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area.

  10. Cartography Receives FDA Investigational New Drug (IND) Approval And Fast Track Designation For Lead Program CBI-1214 For Colorectal Cancer 12/18/2025

    Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application for its lead program, CBI-1214.